Full Text View
Tabular View
No Study Results Posted
Related Studies
Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS (STAR)
This study is ongoing, but not recruiting participants.
Study NCT00573443   Information provided by Avanir Pharmaceuticals
First Received: December 13, 2007   Last Updated: May 3, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Pseudobulbar Affect (PBA)
Additional conditions recognized in this trial
Amyotrophic Lateral Sclerosis
Motor Neuron Disease
Multiple Sclerosis
Sclerosis
More general conditions related to this trial
Autoimmune Diseases
Autoimmune Diseases of the Nervous System
Central Nervous System Diseases
Demyelinating Autoimmune Diseases, CNS
Demyelinating Diseases
Immune System Diseases
Nervous System Diseases
Neurodegenerative Diseases
Neuromuscular Diseases
Pathologic Processes
Spinal Cord Diseases
Interventions listed in this trial
AVP-923
Additional drug interventions recognized in this trial
Dextromethorphan
More general drug interventions related to this trial
Antitussive Agents
Central Nervous System Agents
Excitatory Amino Acid Agents
Excitatory Amino Acid Antagonists
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Pharmacologic Actions
Physiological Effects of Drugs
Respiratory System Agents
Therapeutic Uses
Sponsors listed in this trial
Avanir Pharmaceuticals
Kendle International


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services